Research Progress of HER2 Gene Mutation in Treatment of Breast Cancer
10.3971/j.issn.1000-8578.2023.22.0769
- VernacularTitle:HER2基因突变在乳腺癌治疗中的研究进展
- Author:
Wenjing MENG
1
;
Zhongsheng TONG
Author Information
1. Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy and Key Laboratory of Cancer Prevention and Therapy (Ministry of Education), Tianjin 300060, China
- Publication Type:Research Article
- Keywords:
HER2;
Gene mutation;
Breast cancer
- From:
Cancer Research on Prevention and Treatment
2023;50(2):191-194
- CountryChina
- Language:Chinese
-
Abstract:
HER2 is a tyrosine kinase receptor. It is the main drug target and clinical biomarker for the treatment of breast cancer. About 2% of breast cancer cases has HER2 mutations. Regardless of the expression level or amplification status of HER2, breast cancer with HER2 mutations may respond to targeted HER2 therapy. This article reviews the research progress of HER2 gene mutation in the treatment of breast cancer.
